No major role for insulin-degrading enzyme in antigen presentation by MHC molecules

PLoS One. 2014 Feb 7;9(2):e88365. doi: 10.1371/journal.pone.0088365. eCollection 2014.

Abstract

Antigen presentation by MHC class I molecules requires degradation of epitope source proteins in the cytosol. Although the preeminent role of the proteasome is clearly established, evidence suggesting a significant role for proteasome-independent generation of class I ligands has been reported repeatedly. However, an enzyme responsible for such a role has not been identified. Recently insulin-degrading enzyme (IDE) was shown to produce an antigenic peptide derived from the tumor antigen MAGE-A3 in an entirely proteasome-independent manner, raising the question of the global impact of IDE in MHC class I antigen processing. Here we report that IDE knockdown in human cell lines, or knockout in two different mouse strains, has no effect on cell surface expression of various MHC class I molecules, including allomorphs such as HLA-A3 and HLA-B27 suggested to be loaded in an at least a partly proteasome-independent manner. Moreover, reduced or absent IDE expression does not affect presentation of five epitopes including epitopes derived from beta amyloid and proinsulin, two preferred IDE substrates. Thus, IDE does not play a major role in MHC class I antigen processing, confirming the dominant and almost exclusive role of the proteasome in cytosolic production of MHC class I ligands.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigen Presentation / immunology*
  • Cell Line, Tumor
  • Cytosol / metabolism
  • Genes, MHC Class I / immunology*
  • Histocompatibility Antigens Class I / metabolism
  • Humans
  • Insulysin / genetics
  • Insulysin / metabolism*
  • Mice
  • Mice, Knockout
  • Proteasome Endopeptidase Complex / metabolism

Substances

  • Histocompatibility Antigens Class I
  • Insulysin
  • Proteasome Endopeptidase Complex

Grants and funding

This work was supported by grant 05-Blanc-0162 of the Agence Nationale de Recherche (Paris, France). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.